By Giulia Petroni 

Roche Holding AG said late Monday that the U.S. Food and Drug Administration approved a shorter, two-hour infusion time for ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis.

The Swiss pharmaceutical company said the approval was based on data from the randomized, double-blind "Ensemble Plus" study.

Earlier this year, the drug's two-hour infusion time was approved by the European Medicines Agency.

"More than 170,000 people with multiple sclerosis have been treated with Ocrevus, the only approved B-cell therapy with a twice-yearly dosing schedule," said Levi Garraway, Roche's chief medical officer and head of global product development, referring to the drug by its brand name.


Write to Giulia Petroni at


(END) Dow Jones Newswires

December 15, 2020 02:22 ET (07:22 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.